Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Iovance

3 Stocks to Buy Under $10 That Could Triple From Here

Not all great investment opportunities are expensive.

Iovance Biotherapeutics Declines 29% In Premarket Trading: Here's What's Happening

Iovance Biotherapeutics Declines 29% In Premarket Trading: Here's What's Happening

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) stock has declined by 29.92% in pre-market trading. This comes after the company reported its second-quarter financial results.

3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. Pfizer, Inc. shares traded in a range of $47.27 to $47.95 on day volume of 14.45 million shares, closed…

The Daily Biotech Pulse: BioXcel's Igalmi Gets FDA Nod, Citius Spikes On Positive Phase 3 Data, Iovance Receives Positive Regulatory Feedback For Skin Cancer Therapy

Here's a roundup of top developments in the biotech space over the last 24 hours.

Iovance Outlines Frontline Melanoma Strategy For Lifileucel / Pembrolizumab Combo Therapy

Iovance Receives FDA Allowance For IOV-4001 Study In Two Advanced Cancers

The FDA has signed off Iovance Biotherapeutics Inc's (NASDAQ:IOVA) Investigational New Drug Application (IND) first genetically modified TIL therapy, IOV-4001, for unresectable or metastatic melanoma and stage III or IV non-small-cell lung cancer (NSCLC). IOV-4001 leverages the gene-editing TALEN technology licensed from Cellectis SA (NASDAQ:CLLS). A clinical study of IOV-4001 in patients with metastatic melanoma…

inkl

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Organisations

US Food and Drug Administration

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

332,664 stories

129,642 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play